Table 3 Clinical characteristics, laboratory parameters and coagulation profiles among patients with and without thrombotic complications

Age (years), median (IQR)

57 (49–64)

59 (53–66)

56 (48–63)

0.046

 Female

63 (32)

21 (26)

42 (40)

0.071

 Male

124 (68)

60 (74)

64 (60)

–

APACHE II score, median (IQR)

13 (10–13)

14 (11–18)

13 (9–16)

0.594

ISTH DIC score, median (IQR)

3 (2–3)

3 (2–3)

2 (2–3)

 Prophylactic LMWH or UFH, n

151

59 (31.3)

92 (49.9)

 Therapeutic LMWH or UFH, n

27

18 (9.9)

9 (5.0)

 Vitamin K antagonist, n

2

0 (0)

2 (1.1)

 Directly acting oral anticoagulant, n

2

0 (0)

2 (1.1)

 No anticoagulant, n

3

3 (1.7)

0

 Haemoglobin (g/L) (120–150)

121.1 (20.4)

121.2 (22.9)

121.0 (18.2)

0.948

 Platelet count (×10⁹/L) (150–400)

241 (186–318)

238 (179–319)

243 (193–311)

0.749

 White cell count (×10⁹/L) (4.0–11.0)

9.18 (6.81–12.43)

9.72 (7.82–12.64)

8.16 (6.02–11.55)

0.024

 Lymphocyte count (×10⁹/L) (1.0–4.0)

0.80 (0.50–1.10)

0.80 (0.50–1.10)

0.80 (0.56–1.10)

0.321

 Lactate dehydrogenase

629 (418–927)

700 (437–1032)

579 (415–820)

0.096

 Peak troponin T (ng/mL) (n = 62)

27 (12–57)

44 (23–66)

18 (12–39)

0.008

 Peak troponin I (ng/L) (n = 103)

14 (6–61)

26 (9–194)

9 (4–32)

< 0.001

 CRP (mg/L) (0–5)

202 (128–294)

209 (143–300)

187 (121–267)

0.055

 Ferritin (mcg/l) (10–200)

1126 (495–1880)

1305 (737–2301)

886 (370–1499)

0.008

 Prothrombin time (seconds)

12.4 (11.0–14.9)

12.0 (11.0–13.3)

12.8 (11.0–14.36)

0.499

 D-dimer (ug/mL)

2587 (950–10,000)

6139 (1644–10,000)

1264 (788–5535)

< 0.001

 Fibrinogen (g/L)

7.0 (6.0–10.0)

6.9 (6.0–9.6)

7.4 (6.0–10.0)

0.441

Thromboelastography parameters (n = 20) (normal ranges)

n = 20

n = 12

n = 8

 R time (mins) (4.6–9.1)

7.37 (2.45)

7.70 (1.87)

6.86 (3.22)

0.094

 CK alpha (angle) (63–78)

75.7 (3.4)

75.5 (3.5)

76.1 (3.3)

0.156

 MA (mm) (52–69)

69.3 (2.26)

69.3 (1.70)

69.4 (3.06)

0.169

 Platelet contribution to clot strength (%)

64 (61–73)

63 (53–69)

68 (64–77)

0.552

 Fibrin contribution to clot strength (%)

36 (27–39)

37 (31–47)

32 (23–36)

–

 Thrombodynamic ratio

17.1 (11.5–24.6)

14.1 (11.5–18.0)

24.5 (13.9–24.8)

0.201

 LY30 (0.0–2.6)

0.00 (0.00–0.05)

0.00 (0.00–0.00)

0.00 (0.00–0.48)

0.240

 Died in ICU

59 (31.6)

32 (39.5)

27 (25.5)

0.059

 Still alive in ICU

33 (17.6)

17 (21.0)

16 (15.1)

–

 Discharged alive from ICU

95 (50.8)

32 (39.5)

63 (59.4)

–

ICU length of stay (days), median (IQR)

15 (7–21)

17 (11–27)

12 (7–13)

0.003